New Alzheimer's drug candidate takes first step in human safety trial

NCT ID NCT07660341

Recruiting now Disease control Sponsor: ChainGen Biopharma Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study tests a single intravenous dose of an experimental drug called CGB3002 in healthy adults aged 18 to 55. The main goal is to see if the drug is safe and how the body processes it. This is a first step toward possibly developing a treatment for Alzheimer's disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CGB3002
What this could lead to: If safe, this could open the door to testing CGB3002 as a potential treatment for Alzheimer's disease.
What could go wrong: This is a very early, small study in healthy people, not those with Alzheimer's. It only checks safety and how the drug moves through the body, not whether it works against the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

Nucleus Network
RECRUITING

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.